Public health studies published by the British newspaper "The Financial Times" in its issue today showed that taking two doses of (Biontec-Pfizer) or Oxford-AstraZeneca vaccines against the emerging corona virus "Covid-19" would provide good protection against the B.1.617 strain. 2. Rampant in India.
The newspaper stated in a report published on its website that the latest data, issued in the United Kingdom, indicated the minimum effectiveness available in these vaccines compared to the so-called British Kent variant.
Public health data in England highlighted that the Bionic-Pfizer vaccine offers 88 percent protection against the B.1.617.2 variant found in India, down from the 93 percent provided against the B.1.1.7 strain that was first identified in a county. Kent, southeast England.
She explained that the protection afforded after two doses of the Oxford / AstraZeneca vaccine was lower against both types, 66 per cent for B.1.1.7 and 60 per cent for B.1.617.2.
However, officials cautioned that these numbers are likely to be underestimated, noting that second doses of the AstraZeneca vaccine were introduced at a later date compared to Biontec / Pfizer.
These numbers are expected to boost hopes that the UK government will be able to end the lockdown of the country as planned on June 21, however other data showed that the AstraZeneca vaccine takes several weeks to reach its maximum effectiveness after the second dose, indicating that Its protective effect may not be fully captured in the new data.
For his part, Matt Hancock, Minister of Health and Welfare in the United Kingdom, described the new study as "pioneering", and referring to the number of people who have already received the vaccine doses, Hancock said: "We have now been able to be confident that more than 20 A million people - more than one in every three - enjoy great protection against this new alternative, "a number that was growing in" hundreds of thousands "every day.
Comments
Post a Comment